Pharmaceutical Preparations Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Pharmaceutical Preparations
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Share Price |
Shares Traded |
Shares Owned |
Own chg |
Value Traded |
1d ret |
1w ret |
1m ret |
6m ret |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2017-07-20 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $6.46 | +5,400 | 186,872,356 | 0% | +$34,872 | ||||||
| DM | 2017-07-18 | CORT | Corcept Therapeutics Inc | Mahoney David L | Dir | S - Sale+OE | $12.50 | -23,006 | 1,135,673 | -2% | -$287,597 | |||||
| ADM | 2017-07-12 | CORT | Corcept Therapeutics Inc | Mahoney David L | Dir | S - Sale+OE | $12.50 | -6,994 | 1,135,673 | -1% | -$87,448 | |||||
| D | 2017-07-18 | PTLA | Portola Pharmaceuticals Inc | Fu Tao | EVP, CBO | S - Sale+OE | $65.00 | -5,812 | 0 | -100% | -$377,780 | |||||
| D | 2017-07-18 | PTLA | Portola Pharmaceuticals Inc | Curnutte John T | EVP | S - Sale+OE | $65.00 | -10,000 | 0 | -100% | -$650,000 | |||||
2017-07-20 | KALA | Kala Pharmaceuticals, Inc. | Cdk Associates, L.L.C. | 10% | P - Purchase | $15.00 | +215,000 | 215,000 | New | +$3,225,000 | ||||||
| D | 2017-07-18 | NKTR | Nektar Therapeutics | Gergel Ivan P. | SVP, Chief Medical Officer | S - Sale+OE | $21.10 | -54,920 | 43,572 | -56% | -$1,158,812 | |||||
2017-07-17 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres, 10% | P - Purchase | $0.03 | +39,000 | 21,708,819 | 0% | +$1,064 | ||||||
2017-07-17 | IMMY | Imprimis Pharmaceuticals, Inc. | Kammer Robert J | Dir | S - Sale | $3.05 | -10,000 | 1,059,827 | -1% | -$30,526 | ||||||
| D | 2017-07-17 | VRTX | Vertex Pharmaceuticals Inc / Ma | Chodakewitz Jeffrey | EVP GMDA, CMO | S - Sale+OE | $129.85 | -573 | 122,511 | 0% | -$74,402 | |||||
| D | 2017-07-17 | PRTA | Prothena Corp Plc | Henney Christopher S | Dir | S - Sale+OE | $66.13 | -5,000 | 0 | -100% | -$330,671 | |||||
2017-07-17 | CALA | Calithera Biosciences, Inc. | Wong Stephanie | VP, FINANCE, SECRETARY | S - Sale | $18.41 | -3,552 | 13,050 | -21% | -$65,385 | ||||||
| D | 2017-07-17 | PRTA | Prothena Corp Plc | Walker Karin L | See Remarks | S - Sale+OE | $64.89 | -5,000 | 0 | -100% | -$324,439 | |||||
2017-07-17 | CALA | Calithera Biosciences, Inc. | Orford Keith | SVP, CLINICAL DEVELOPMENT | S - Sale | $18.31 | -2,120 | 6,879 | -24% | -$38,823 | ||||||
| M | 2017-07-14 | NBRV | Nabriva Therapeutics Plc | Hbm Healthcare Investments (Cayman) Ltd. | 10% | S - Sale | $10.51 | -69,854 | 2,442,153 | -3% | -$734,264 | |||||
2017-07-14 | ICPT | Intercept Pharmaceuticals Inc | Kim Richard J | SVP, Commercial US | S - Sale | $128.64 | -89 | 11,253 | -1% | -$11,449 | ||||||
| D | 2017-07-14 | NKTR | Nektar Therapeutics | Lingnau Lutz | Dir | S - Sale+OE | $20.76 | -30,000 | 23,450 | -56% | -$622,800 | |||||
2017-07-18 | ALDR | Alder Biopharmaceuticals Inc | Yarno Wendy L | Dir | P - Purchase | $10.00 | +5,000 | 5,000 | New | +$50,000 | ||||||
2017-07-18 | ALDR | Alder Biopharmaceuticals Inc | Dow Stephen M | Dir | P - Purchase | $10.00 | +25,000 | 307,190 | +9% | +$250,000 | ||||||
| D | 2017-07-17 | IONS | Ionis Pharmaceuticals Inc | Crooke Stanley T | COB, CEO | S - Sale+OE | $52.45 | -16,500 | 766,467 | -2% | -$865,425 | |||||
2017-07-17 | JAZZ | Jazz Pharmaceuticals Plc | Miller Michael Patrick | EVP, US Commercial | S - Sale | $154.97 | -200 | 22,196 | -1% | -$30,994 | ||||||
| D | 2017-07-14 | CARA | Cara Therapeutics, Inc. | Chalmers Derek T | Pres, CEO | S - Sale+OE | $15.05 | -25,000 | 1,082,292 | -2% | -$376,250 | |||||
2017-07-14 | CARA | Cara Therapeutics, Inc. | Menzaghi Frederique Ph.D. | VP-Research, Development | S - Sale | $15.00 | -3,000 | 120,000 | -2% | -$45,000 | ||||||
2017-07-17 | FGEN | Fibrogen Inc | Kurkijarvi Kalevi | Dir | S - Sale | $33.45 | -2,000 | 32,000 | -6% | -$66,900 | ||||||
2017-07-14 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres, 10% | P - Purchase | $0.03 | +700 | 21,669,819 | 0% | +$18 | ||||||
| M | 2017-07-13 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres, 10% | P - Purchase | $0.03 | +98,770 | 21,669,119 | 0% | +$2,626 | |||||
| D | 2017-07-17 | M | Kubota Pharmaceutical Holdings Co Ltd | Scheibler Lukas | EVP of Research, Development | S - Sale+OE | $6.50 | -1,250 | 11,108 | -10% | -$8,125 | |||||
2017-07-17 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $6.04 | +1,800 | 186,866,956 | 0% | +$10,871 | ||||||
2017-07-17 | CLVS | Clovis Oncology, Inc. | Ivers-Read Gillian C | See Remarks | S - Sale | $91.56 | -3,000 | 197,583 | -1% | -$274,680 | ||||||
| DM | 2017-07-13 | AIMT | Aimmune Therapeutics, Inc. | Rozenman Mary M. | See Remarks | S - Sale+OE | $21.44 | -14,940 | 129 | -99% | -$320,247 | |||||
| D | 2017-07-13 | BLCM | Bellicum Pharmaceuticals, Inc | Moseley Ken | SVP, GC | S - Sale+OE | $12.26 | -13,823 | 1,126 | -92% | -$169,470 | |||||
2017-07-14 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $6.16 | +12,600 | 186,865,156 | 0% | +$77,564 | ||||||
| D | 2017-07-03 | PBYI | Puma Biotechnology, Inc. | Bryce Richard Paul | SVP, CLINICAL RESEARCH, DEV | S - Sale+OE | $87.10 | -5,000 | 29,237 | -15% | -$435,500 | |||||
| M | 2017-07-12 | CORT | Corcept Therapeutics Inc | Mahoney David L | Dir | S - Sale | $12.50 | -6,994 | 1,128,679 | -1% | -$87,448 | |||||
2017-07-12 | KIN | Kindred Biosciences, Inc. | Park West Asset Management LLC | 10% | P - Purchase | $7.50 | +600,000 | 5,156,791 | +13% | +$4,500,000 | ||||||
| D | 2017-07-13 | UTHR | United Therapeutics Corp | Rothblatt Martine A | COB, CEO | S - Sale+OE | $130.44 | -1,238 | 665,144 | 0% | -$161,486 | |||||
2017-07-13 | AMAG | Amag Pharmaceuticals Inc. | Krop Julie | SVP Clinical, Regulatory, CMO | S - Sale | $20.00 | -4,938 | 28,336 | -15% | -$98,760 | ||||||
2017-07-12 | SUPN | Supernus Pharmaceuticals Inc | Bhatt Padmanabh P. | SVP of IP, CSO | S - Sale | $44.90 | -3,735 | 21,209 | -15% | -$167,702 | ||||||
| M | 2017-07-10 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres, 10% | P - Purchase | $0.03 | +31,000 | 21,570,349 | 0% | +$921 | |||||
2017-07-13 | FOLD | Amicus Therapeutics Inc | Perceptive Advisors LLC | 10% | P - Purchase | $12.25 | +1,500,000 | 17,888,597 | +9% | +$18,375,000 | ||||||
| M | 2017-07-11 | NBRV | Nabriva Therapeutics Plc | Hbm Healthcare Investments (Cayman) Ltd. | 10% | S - Sale | $10.53 | -57,175 | 2,512,007 | -2% | -$602,056 | |||||
2017-07-11 | ICPT | Intercept Pharmaceuticals Inc | Shapiro David | CMO, EVP - Development | S - Sale | $124.01 | -553 | 44,562 | -1% | -$68,578 | ||||||
| DM | 2017-07-11 | NKTR | Nektar Therapeutics | Gergel Ivan P. | SVP, Chief Medical Officer | S - Sale+OE | $21.08 | -45,080 | 43,572 | -51% | -$950,318 | |||||
| DM | 2017-07-11 | CCXI | Chemocentryx, Inc. | Bekker Petrus | Chief Medical Officer | S - Sale+OE | $9.95 | -76,013 | 59,839 | -56% | -$756,070 | |||||
2017-07-12 | BGNE | Beigene, Ltd. | Wang Xiaodong | Dir | S - Sale | $72.44 | -20,000 | 12,739,924 | 0% | -$1,448,704 | ||||||
| D | 2017-07-11 | PTLA | Portola Pharmaceuticals Inc | Dier Mardi | EVP, CFO | S - Sale+OE | $60.00 | -23,350 | 0 | -100% | -$1,401,000 | |||||
2017-07-12 | WVE | Wave Life Sciences Ltd. | Panzara Michael A. | Franchise Lead, Neurology | S - Sale | $16.67 | -7,414 | 15,336 | -33% | -$123,620 | ||||||
2017-07-11 | KDMN | Kadmon Holdings, Inc. | Goldentree Asset Management LP | 10% | S - Sale | $3.69 | -34,462 | 1,631,665 | -2% | -$127,165 | ||||||
2017-07-12 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $6.12 | +3,600 | 186,852,556 | 0% | +$22,050 | ||||||
2017-07-10 | BGNE | Beigene, Ltd. | Glazer Donald W. | Dir | S - Sale | $72.15 | -10,810 | 4,565,794 | 0% | -$779,900 | ||||||
| M | 2017-07-10 | IMDZ | Immune Design Corp. | Coleman Lewis W | Dir | P - Purchase | $9.05 | +12,000 | 63,000 | +24% | +$108,600 | |||||
| D | 2017-07-10 | PTGX | Protagonist Therapeutics, Inc | Liu David Y | Chief Scientific Officer | S - Sale+OE | $12.68 | -3,500 | 2,000 | -64% | -$44,380 | |||||
2017-07-10 | BLCM | Bellicum Pharmaceuticals, Inc | Spencer David M. | Chief Scientific Officer | S - Sale | $11.54 | -10,000 | 138,965 | -7% | -$115,400 | ||||||
2017-07-11 | ZFGN | Zafgen, Inc. | Kim Dennis D | Chief Medical Officer | P - Purchase | $3.39 | +10,000 | 21,443 | +87% | +$33,900 | ||||||
| M | 2017-07-11 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres, CEO, COB, 10% | P - Purchase | $0.29 | +4,000 | 3,838,957 | 0% | +$1,150 | |||||
2017-07-10 | FGEN | Fibrogen Inc | Yu K Peony | Chief Medical Officer | S - Sale | $32.98 | -5,000 | 216,507 | -2% | -$164,900 | ||||||
2017-07-05 | AKBA | Akebia Therapeutics, Inc. | Satter Muneer A | Dir | P - Purchase | $14.50 | +1,034,482 | 3,037,042 | +52% | +$14,999,989 | ||||||
| D | 2017-07-07 | AGIO | Agios Pharmaceuticals Inc | Biller Scott | Chief Scientific Officer | S - Sale+OE | $55.00 | -2,146 | 52,734 | -4% | -$118,030 | |||||
2017-07-07 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres, 10% | P - Purchase | $0.03 | +10,000 | 21,539,349 | 0% | +$292 | ||||||
2017-07-10 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $6.19 | +50,000 | 186,848,956 | 0% | +$309,570 | ||||||
| DM | 2017-07-07 | CCXI | Chemocentryx, Inc. | Bekker Petrus | Chief Medical Officer | S - Sale+OE | $9.30 | -19,877 | 59,839 | -25% | -$184,856 | |||||
| M | 2017-07-06 | IMDZ | Immune Design Corp. | Coleman Lewis W | Dir | P - Purchase | $9.27 | +8,000 | 51,000 | +19% | +$74,150 | |||||
2017-07-06 | BGNE | Beigene, Ltd. | Oyler John | CEO, 10% | S - Sale | $64.82 | -219,400 | 69,185,550 | 0% | -$14,221,125 | ||||||
| AD | 2017-06-15 | SELB | Selecta Biosciences Inc | Johnston Lloyd P. | COO, SVP, R, D | S - Sale+OE | $17.04 | -10,512 | 1,606 | -87% | -$179,141 | |||||
| M | 2017-07-05 | NBRV | Nabriva Therapeutics Plc | Hbm Healthcare Investments (Cayman) Ltd. | 10% | S - Sale | $10.52 | -2,695 | 2,569,182 | 0% | -$28,357 | |||||
| M | 2017-07-05 | PAHC | Phibro Animal Health Corp | Bfi Co., LLC | 10% | S - Sale | $36.49 | -32,000 | 12,000 | -73% | -$1,167,680 | |||||
| M | 2017-07-05 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $36.49 | -32,000 | 12,000 | -73% | -$1,167,680 | |||||
| D | 2017-07-05 | ALRN | Aileron Therapeutics Inc | Shanafelt Armen | Dir | P - Purchase | $15.00 | +250,000 | 1,094,987 | +30% | +$3,750,000 | |||||
| D | 2017-07-05 | ALRN | Aileron Therapeutics Inc | Lv Management Group, LLC | Former 10% owner | P - Purchase | $15.00 | +250,000 | 1,094,987 | +30% | +$3,750,000 | |||||
| D | 2017-07-05 | ALRN | Aileron Therapeutics Inc | Aju Ib Investment Co., Ltd. | 10% | P - Purchase | $15.00 | +24,929 | 517,558 | +5% | +$373,935 | |||||
| DM | 2017-07-06 | FGEN | Fibrogen Inc | Neff Thomas B | CEO | S - Sale+OE | $33.38 | -38,636 | 3,528,700 | -1% | -$1,289,547 | |||||
2017-07-05 | RIGL | Rigel Pharmaceuticals Inc | Duliege Anne-Marie | Chief Medical Officer | S - Sale | $2.69 | -5,000 | 0 | -100% | -$13,427 | ||||||
| D | 2017-07-07 | PRTA | Prothena Corp Plc | Selkoe Dennis J. | Dir | S - Sale+OE | $58.11 | -3,500 | 4,208 | -45% | -$203,399 | |||||
2017-07-07 | CLSN | Celsion Corp | Fritz Frederick J. | Dir | P - Purchase | $1.89 | +13,000 | 16,341 | +389% | +$24,570 | ||||||
2017-07-05 | BPMC | Blueprint Medicines Corp | Lynch Daniel | Dir | S - Sale | $55.06 | -7,500 | 211,842 | -3% | -$412,950 | ||||||
| D | 2017-07-05 | BPMC | Blueprint Medicines Corp | Haviland Kate | Chief Business Officer | S - Sale+OE | $54.66 | -7,265 | 0 | -100% | -$397,077 | |||||
| D | 2017-07-06 | FGEN | Fibrogen Inc | Cotroneo Pat | VP, Finance, CFO | S - Sale+OE | $34.00 | -4,000 | 163,366 | -2% | -$136,000 | |||||
| D | 2017-07-06 | UTHR | United Therapeutics Corp | Rothblatt Martine A | COB, CEO | S - Sale+OE | $132.29 | -1,234 | 664,206 | 0% | -$163,247 | |||||
2017-07-06 | CALA | Calithera Biosciences, Inc. | Hecht Curtis | SVP, BUS., CORP. DEVELOPMENT | S - Sale | $18.00 | -700 | 15,940 | -4% | -$12,600 | ||||||
2017-07-05 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres, CEO, COB, 10% | P - Purchase | $0.28 | +2,000 | 3,834,957 | 0% | +$565 | ||||||
| M | 2017-07-03 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres, 10% | P - Purchase | $0.03 | +28,000 | 21,529,349 | 0% | +$855 | |||||
2017-07-05 | DOVA | Dova Pharmaceuticals, Inc. | Manning Paul B | Dir, 10% | P - Purchase | $17.00 | +150,000 | 14,098,179 | +1% | +$2,550,000 | ||||||
2017-07-05 | DOVA | Dova Pharmaceuticals, Inc. | Allen Lee F Md Phd | Chief Medical Officer | P - Purchase | $17.00 | +3,500 | 3,500 | New | +$59,500 | ||||||
2017-07-05 | DOVA | Dova Pharmaceuticals, Inc. | Laliberte Kevin | SVP, Product Development | P - Purchase | $17.00 | +6,200 | 6,200 | New | +$105,400 | ||||||
2017-07-05 | DOVA | Dova Pharmaceuticals, Inc. | Jeffs Roger | Dir | P - Purchase | $17.00 | +31,400 | 31,400 | New | +$533,800 | ||||||
2017-07-05 | DOVA | Dova Pharmaceuticals, Inc. | Goldman Steven M. | Dir | P - Purchase | $17.94 | +72,000 | 72,000 | New | +$1,291,500 | ||||||
2017-07-05 | DOVA | Dova Pharmaceuticals, Inc. | Sapir Alex | Pres, CEO | P - Purchase | $17.00 | +20,100 | 20,100 | New | +$341,700 | ||||||
2017-07-06 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $6.29 | +25,000 | 186,798,956 | 0% | +$157,141 | ||||||
| D | 2017-07-03 | ADRO | Aduro Biotech, Inc. | Lew Jennifer | SVP of Finance | S - Sale+OE | $11.14 | -12,000 | 42,595 | -22% | -$133,632 | |||||
| DM | 2017-07-03 | ADRO | Aduro Biotech, Inc. | Isaacs Stephen T | Pres, CEO | S - Sale+OE | $11.06 | -40,000 | 174,682 | -19% | -$442,397 | |||||
| D | 2017-07-03 | ADRO | Aduro Biotech, Inc. | Brockstedt Dirk G. | EVP of Research, Dev. | S - Sale+OE | $11.02 | -10,000 | 49,300 | -17% | -$110,167 | |||||
| DM | 2017-07-03 | ADRO | Aduro Biotech, Inc. | Dubensky Thomas W. | Chief Scientific Officer | S - Sale+OE | $11.33 | -50,000 | 39,900 | -56% | -$566,638 | |||||
| D | 2017-07-05 | ALRN | Aileron Therapeutics Inc | Gallagher Brian M. Jr. | Dir | P - Purchase | $15.00 | +273,333 | 1,431,519 | +24% | +$4,099,995 | |||||
| D | 2017-07-05 | ALRN | Aileron Therapeutics Inc | Sigma Emerging Markets Ltd. | 10% | P - Purchase | $15.00 | +190,000 | 423,086 | +82% | +$2,850,000 | |||||
| D | 2017-07-05 | ALRN | Aileron Therapeutics Inc | Excel Medical Fund LP | 10% | P - Purchase | $15.00 | +60,000 | 1,016,100 | +6% | +$900,000 | |||||
| D | 2017-07-05 | ALRN | Aileron Therapeutics Inc | Satter Muneer A | 10% | P - Purchase | $15.00 | +33,333 | 178,106 | +23% | +$499,995 | |||||
2017-07-05 | KERX | Keryx Biopharmaceuticals Inc | Madison Greg | Pres, CEO | S - Sale | $7.67 | -910 | 377,768 | 0% | -$6,980 | ||||||
2017-07-05 | KERX | Keryx Biopharmaceuticals Inc | Adams Brian | GC, Secretary | S - Sale | $7.67 | -641 | 137,495 | 0% | -$4,916 | ||||||
2017-07-03 | KIN | Kindred Biosciences, Inc. | Chin Richard | Pres, CEO, 10% | S - Sale | $8.26 | -13,000 | 2,297,546 | -1% | -$107,380 | ||||||
| M | 2017-07-03 | EDGE | Edge Therapeutics, Inc. | Leuthner Brian A | Pres, CEO | S - Sale | $10.19 | -7,500 | 513,358 | -1% | -$76,400 |
Real-time CSV? Options? Alerts? Contact us!
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |